References:

 

1- T.D.DuBose Jr. American Society of Nephrology Presidential Address 2006: Chronic Kidney Disease as a Public Health Threat--New Strategy for a Growing Problem J. Am. Soc. Nephrol 1; 18(4): 1038 – 1045, 2007.

2- B.R.Hemmelgarn,B.J. Manns, J. Zhang, M. Tonelli, S. Multidisciplinary Care and Survival for Elderly Patients with Chronic Kidney Disease J. Am. Soc. Nephrol., March 1, 2007; 18(3): 993 - 999.

3- S.V. Jassal MB BCh MD, L. Trpeski MPH MD, N. Zhu MD, S. Fenton MD, and B. Hemmelgarn PhD MD Changes in survival among elderly patients initiating dialysis from 1990 to 1999 Can. Med. Assoc. J., October 23, 2007; 177(9): 1033 - 1038.

4- Locatelli F, Marcelli D, Conte F, D’Amico M, Del Vecchio L, Limido A, Malberti F, Spotti D: Survival and development of cardiovascular disease by modality of treatment in patients with end-stage renal disease. J Am Soc Nephrol 12: 2411–2417, 2001.

5- Salonen T, Reina T, Oksa H et al. Cost analysis of renal replacement therapies in Finland. Am J Kidney Dis 2003; 42: 1228–1238.

6- P.K.Mitra and J. R Bradley Chronic kidney disease in primary care J. R. Soc. Med., January 1; 100(1): 40 – 45 2007.

7- Sydney C. W. Tang, Yiu Wing Ho, Anthony W. C. Tang et al. Delaying initiation of dialysis till symptomatic uraemia—is it too late? Nephrol Dial Transplant 2007 22(7):1926-1932

8- Wolfgang C. Winkelmayer*, William F. Owen, A Propensity Analysis of Late Versus Early Nephrologist Referral and Mortality on Dialysis J Am Soc Nephrol 14:486-492, 2003

9- R. M. Huisman The deadly risk of late referral. Nephrol. Dial. Transplant., September 1, 2004; 19(9): 2175 -2180

10- W. H. Kazmi, G. T. Obrador, S. S. Khan.Late nephrology referral and mortality among patients with end-stage renal disease: a propensity score analysis.Nephrol. Dial. Transplant., July 1, 2004; 19(7): 1808 - 1814.

11- The rising global burden of diabetes and its complications: estimates and projections to the year 2010”, Diabet. Med. (1997);14(suppl. 5): pp. S1–S85.

12- Ritz E, Rychlik I, Locatelli F, Halimi S, “End-stage renal failure in type 2 diabetes: A medical catastrophe of worldwide dimensions”, Am. J. Kidney Dis. (1999); 34: ppp. 795–808.

13- Al-Amrani, M., The use of qat and its legal issue. Al-Irsahd Magazine, Sana’a. 1979

14- Carapico, S., Yemeni agriculture in transition. In P. Beaumont and K. McLachlan, eds., Agricultural Development in the Middle East. New York: John Wiley and Sons Ltd. 1985: 241 – 254

15- Hassan NAGM, Gunaid AA, El Khally FMY, Murray-Lyon IM. The subjective effects of chewing qat leaves in human volunteers. Annals of Saudi Medicine 2003; 22(1–2): 34–37

16- CYS, Qat in Yemen and in Yemeni Life (in Arabic). Center for Yemeni Studies, Sana’a, CYS, 1982: 341 pp

17- Klag MJ, Whelton PK, Randell BL, Neaton JD, Brancati FL, Ford CE, Shulman NB, Stamler J. Blood pressure and end-stage renal disease in men. N Engl J Med 1996; 334:13–18.

18- Halbach, H., 1972. Medical aspects of the chewing of khat leaves. Bulletin of the World Health Organization 47, 21 – 29

19- Kalix P. Pharmacological properties of the stimulant khat. Pharmacol Ther 1990; 48: 397–416

20- Hes, J., 1970. On the use of Catha edulis among Yemenite Jews. Journal of the Israel Medical Association 78:6, 283 - 284

21- European Renal Association-European Dialysis and Transplant Association. ERA-EDTA Registry 2004 Annual Report. Amsterdam, the Netherlands: Department of Medical Informatics, Academic Medical Center; 2006.

22- Goodkin DA,Young EW, Kurokawa K et al. Mortality among hemodialysis patients in Europe, Japan, and the United States: case-mix effects. Am J Kidney Dis 44: 16–21, 2004

23- Jungers P, Massy ZA, Nguyen-Khoa T, Choukroun G, Robino C, Fakhouri F, Touam M, Nguyen AT, Grünfeld JP: Longer duration of predialysis nephrological care is associated with improved long-term survival of dialysis patients. Nephrol Dial Transplant 16: 2357–2364, 2001.

24- Adult-to-Adult Living Related Donor Renal Transplantation in Yemen: The First Experience. Saudi J Kdney Dis Transplant. 2007 : (18) : 265-269.

25- Collins AJ, Kasiske B, Herzog C, et al. Excerpts from the United States Renal Data System 2003 Annual Data Report: atlas of end-stage renal disease in the United States. Am J Kidney Dis. 2003;42(6 suppl 5):A5–A7.

26- Kalantar-Zadeh K, Block G, Humphreys MH, Kopple JD. Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int 2003;63:793-808.

27- Wright JT, et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease. JAMA November 20, 2002;288:2421-31

28- Weber MJ. Natural history of hypertension. J Hypertension. Kidney Int 2003;21(suppl 6):S37-S46.

29- Rodicio JL, Alcazar JM, Ruilope LM. Influence of converting enzyme inhibition on glomerular filtration rate and proteinuria. Kidney Int 1990; 38: 590-594.

30- Molitch ME, DeFronzo RA, Franz MJ, Keane WF, Mogensen CE, Parving HH; American Diabetes Association 2003 Diabetic nephropathy. Diabetes Care 26(Suppl 1):S94–S98

31- Finne P, Reunanen A, Stenman S, Groop PH, Gronhagen-Riska C 2005 Incidence of end-stage renal disease in patients with type 1 diabetes. JAMA 294:1782–1787

32- Badheeb AM. Causes of Chronic Renal Failure in Hemodialysis Unit: A single center experience in Yemen. Saudi J Kidney Dis Transpl 2006;17:66-69.

33- Dannenberg AL, Kannel WB: Remission of hypertension.The ‘natural’ history of blood pressure treatment in the Framingham Study. JAMA 257: 1477–1483, 1987

34- Foley RN, Parfrey PS, Sarnak MJ. Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol 1998; 9:S16-S23.

35- Ruilope LM: Renal function and cardiovascular risk in hypertensive patients. J Hypertens 23: 1787–1788, 2005.

36- De Leeuw PW, Ruilope LM, Palmer CR, Brown MJ, Castaigne A, Mancia G, Rosenthal T, Wagener G: Clinical significance of renal function in hypertensive patients at high risk: Results from the INSIGHT trial. Arch Intern Med 164: 2459–2464, 2004.

37- RuggenentiP, SchieppatiA, RemuzziG.Progression, remission, regression of chronic renal diseases. Lancet2001; 357:1601–1608.

38- Formica R N, “CKD series: Delaying the progression of chronic kidney disease”, Hosp. Physician (2003);43: pp. 24–33.

39- Jones C A, “Hypertension and renal dysfunction: NHANES III”, J. Am. Soc. Nephrol. (2003);14: pp. S71–S75.

40- Risk Factors for Progressive Chronic Kidney Disease.J. Am. Soc. Nephrol., July 1, 2003; 14(90002): S65 - 70.

41- McClellan W M, Flanders W D, “Risk factors for progressive chronic kidney disease”, J. Am. Soc. Nephrol. (2003);14: pp. S65–S70.

42- Coresh J, Astor B C, Greene T, Eknoyan G, Levey A S, “Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey”, Am. J. Kidney Dis.(2003);41: pp. 1–12.

43- Levey A S, Coresh J, Balk E et al., “National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification”, Ann. Intern. Med. (2003);139: pp. 137–147.

44- Lingeman JE, Siegel YI, Steele B: Metabolic evaluation of infected renal lithiasis: clinical relevance. J Endourol 9: 51-55,1995.

45- Ahlstrand C, Tiselius HG: Recurrences during a 10 years follow-up alter final renal stone episode. Urol Res 18: 397-399,1990

46- Avorn J, Winkelmayer WC, Bohn RL, Levin R, Glynn RJ, Levy E, Owen W: Delayed nephrologist referral and inadequate vascular access in patients with advanced kidney failure. J Clin Epi 55: 711–716, 2002.

47- Cimochowski GE, Worley E, Rutherford WE, Sartain J, Blondin J, Harter H: Superiority of the internal jugular over the subclavian access for temporary dialysis. Nephron 54:154–161, 1990

48- National Kidney Foundation. K/DOQI clinical practice guidelines for vascular access, 2000. Am J Kidney Dis 2001; 37(suppl 1):S137-S181.

49- E. A. Krzywda and D. A. AndrisTwenty-five Years of Advances in Vascular Access: Bridging Research to Clinical Practice Nutr Clin Pract, December 1, 2005; 20(6): 597 - 606.

50- Mickley V: Central venous catheters: many questions, few answers. Nephrol Dial Transplant 17:1368–1373, 2002

51- MacRae JM, Ahmed A, Johnson N, Levin A, Kiaii M: Central vein stenosis: a common problem in patients on hemodialysis. ASAIO J 51:77–81, 2005

52- Stack AG. Impact of timing of nephrology referral and pre-ESRD care on mortality risk among new ESRD patients in the United States. Am J Kidney Dis; 41: 310–318 2003.

53- Roubicek C, Brunet P, Huiart L, Thirion X, Leonetti F, Dussol B, Jaber K, Andrieu D, Ramananarivo P, Berland Y: Timing of nephrology referral: Influence on mortality and morbidity. Am J Kidney Dis 36: 35–41, 2000

54- V. Schwenger, C. Morath, A. Hofmann, O. Hoffmann, M. Zeier, and E. Ritz Late referral - a major cause of poor outcome in the very elderly dialysis patient Nephrol. Dial. Transplant. April 1, 2006; 21(4): 962 – 967.

55- Fergus J. Caskey,, Sarah Wordsworth.Early referral and planned initiation of dialysis: what impact on quality of life? Nephrol Dial Transplant (2003) 18: 1330-1338.

56- Traynor JP, Simpson K, Geddes CC, Deighan CJ, Fox JG. Early initiation of dialysis fails to prolong survival in patients with end-stage renal failure. J Am Soc Nephrol (2002) 13:2125–2132.

57- Fabrizi F, Lunghi G, Raffaele L, et al. Serologic survey for control of hepatitis C in haemodialysis patients: third-generation assays and analysis of costs. Nephrol Dial Transplant 1997;12(2):298-303.

58- Flamm, S. L. Chronic hepatitis C virus infection. JAMA 289:2413-2417. 2003.

59- Petrosillo N, Gilli P, Serraino D, et al. Prevalence of infected patients and understaffing have a role in hepatitis C virus transmission in dialysis. Am J Kidney Dis 2001;37(5):1004-10.

60- Okuda, K., H. Hayashi, S. Kobayashi, and Y. Irie. 1995. Mode of hepatitis C infection not associated with blood transfusion among chronic hemodialysis patients. J. Hepatol. 23:28-31.

61- Huraib SO. Hepatitis C in dialysis patients. Saudi J Kidney Dis Transplant 2003; 14(4):442-50.61-Tokars JI, Alter MJ, Arduino MJ. Nosocomial infections in hemodialysis units: strategies for control. In: Owen WF, Pereira BJG, Sayegh MH, eds. Dialysis and transplantation: a companion to Brenner and Rector's THE KIDNEY. Philadelphia, PA: W.B. Saunders Company, 2000:337—57

62- Orth SR, Ogata H, Ritz E. Smoking and the kidney. Nephrol Dial Transplant. 2000; 15:1509–1511

63- Orth SR: Smoking: A renal risk factor. Nephron 86: 12–26, 2000

64- Halimi JM, Giraudeau B, Vol S, Caces E, Nivet H, Lebranchu Y, Tichet J: Effects of current smoking and smoking discontinuation on renal function and proteinuria in the general population. Kidney Int 58: 1285–1292, 2000

65- Stephan R. Orth.Effects of Smoking on Systemic and Intrarenal Hemodynamics: Influence on Renal Function J Am Soc Nephrol 15:S58-S63, 2004

66- Bleyer AJ, Shemanski LR, Burke GL, Hansen KJ, Appel RG: Tobacco, hypertension, and vascular disease: Risk factors for renal functional decline in an older population. Kidney Int 57: 2072–2079, 2000.

67- Mohamed A O et al Morbidity and Mortality in ESRD Patients on Regular Hemodialysis: A Single Center Experience Saudi.J Kidney Dis Transplant 2005 : 16: 3: 336-341

68- Jula K. Inrig, Jie L. Sun, Qinghong Yang Mortality by Dialysis Modality among Patients Who Have End-Stage Renal Disease and Are Awaiting Renal Transplantation Clin J Am Soc Nephrol 1: 774-779, 2006.

69- Brian D. Bradbury*, Rachel B. Fissell Predictors of Early Mortality among Incident US Hemodialysis Patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS) Clin J Am Soc Nephrol 2: 89-99, 2007

70- Waqar H. Kazmi, Gregorio T. Obrador, Samina S. KhanLate nephrology referral and mortality among patients with end-stage renal disease: a propensity score analysis Nephrol Dial Transplant (2004) 19: 1808-1814

71- C P Kovesdy Regional mortality differences in end-stage renal disease: How far can observational studies take us? Kidney Int. (2007) 71, 11–12